First Patient Treated In BioInvent’s Phase I Study Of The Drug Candidate BI-505 To Treat Multiple Myeloma

BioInvent International AB (STO:BINV) announced that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma. “We are delighted that the clinical studies of BI-505 have started…

More: continued here

Filed under: Blood on January 5th, 2010